Ivonescimab Lung Cancer Treatment Data in China Presented at ASCO

Chicago, IL – Recent data presented at the American Society for Clinical Oncology (ASCO) in Chicago highlighted findings related to Summit Therapeutics’ ivonescimab in a Chinese study. Analysts at BMO Capital Markets noted the continued prominence of Keytruda in the oncology landscape following the release of this data.

The data, which focused on the use of ivonescimab in lung cancer treatment within China, has drawn attention to its potential impact. The study’s results have sparked discussions about the drug’s efficacy and its role in comparison to existing treatments like Keytruda. While the Chinese data provides initial insights, further research is needed to determine the global benefits and broader applicability of ivonescimab in diverse patient populations and healthcare settings.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 1, 2026

Author

GOAI